Optimal study design for pioglitazone in septic pediatric patients

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 38, Issue 4, 2011, Pages 433-447

  Sherwin, Catherine M T ^a,c   Ding, Lili ^a   Kaplan, Jennifer ^a,b   Spigarelli, Michael G ^a,b   Vinks, Alexander A ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Optimal design; Pediatric; Pioglitazone; Sepsis; Sparse sampling

Indexed keywords

PIOGLITAZONE;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHILD; COMPARATIVE STUDY; COMPUTER PROGRAM; DIABETES MELLITUS; DISEASE SEVERITY; DRUG HALF LIFE; HUMAN; MATHEMATICAL MODEL; PHARMACOKINETICS; POPULATION DYNAMICS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEPSIS; SEPTIC SHOCK; SIMULATION; SINGLE DRUG DOSE; STUDY DESIGN;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DIABETES COMPLICATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, BIOLOGICAL; RESEARCH DESIGN; SAMPLE SIZE; SEPSIS; THIAZOLIDINEDIONES;

EID: 80052590070     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-011-9202-8     Document Type: Article

References (27)

1. Eckland DA, Danhof M (2000) Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol Diabetes 108:234-242
2. Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-86 (Pubitemid 28079219)
3. Zingarelli B, Sheehan M, Hake PW, O'Connor M, Denenberg A, Cook JA (2003) Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy-Delta(12, 14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J Immunol 171:6827-6837 (Pubitemid 37532118)
4. Collin M, Patel NS, Dugo L, Thiemermann C (2004) Role of peroxisome proliferator-activated receptor-gamma in the protection afforded by 15-deoxydelta12, 14 prostaglandin J2 against the multiple organ failure caused by endotoxin. Crit Care Med 32:826-831 (Pubitemid 38340084)
5. Kaplan JM, Cook JA, Hake PW, O'Connor M, Burroughs TJ, Zingarelli B (2005) 15-deoxy-delta12, 14-prostaglandin J2 (15D-PGJ2), a peroxisome proliferator activated receptor gamma ligand, reduces tissue leukosequestration and mortality in endotoxic shock. Shock 24:59-65 (Pubitemid 40946596)
6. Kuboki S, Shin T, Huber N, Eismann T, Galloway E, Schuster R, Blanchard J, Zingarelli B, Lentsch AB (2008) Peroxisome proliferator-activated receptor-gamma protects against hepatic ischemia/reperfusion injury in mice. Hepatology 47:215-224 (Pubitemid 351171059)
7. Zingarelli B, Hake PW, Mangeshkar P, O'Connor M, Burroughs TJ, Piraino G, Denenberg A, Wong HR (2007) Diverse cardioprotective signaling mechanisms of peroxisome proliferator-activated receptor-gamma ligands, 15-deoxy-Delta12, 14-prostaglandin J2 and ciglitazone, in reperfusion injury: role of nuclear factor-kappaB, heat shock factor 1, and Akt. Shock 28:554-563 (Pubitemid 350287432)
8. Chima RS, Hake PW, Piraino G, Mangeshkar P, Denenberg A, Zingarelli B (2008) Ciglitazone ameliorates lung inflammation by modulating the inhibitor kappaB protein kinase/nuclear factor-kappaB pathway after hemorrhagic shock. Crit Care Med 36:2849-2857
9. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303-1310 (Pubitemid 32641789)
10. Watson RS, Carcillo JA, Linde-Zwirble WT, Clermont G, Lidicker J, Angus DC (2003) The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 167:695-701 (Pubitemid 36801744)
11. Bone RC, Sibbald WJ, Sprung CL (1992) The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 101:1481-1483
12. Christensen ML, Meibohm B, Capparelli EV, Velasquez-Mieyer P, Burghen GA, Tamborlane WV (2005) Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes. J Clin Pharmacol 45:1137-1144 (Pubitemid 41361913)
13. Budde K, Neumayer HH, Fritsche L, Sulowicz W, Stompor T, Eckland D (2003) The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 55:368-374 (Pubitemid 36535367)
14. Anderson BJ, Holford NH (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303-332 (Pubitemid 351738156)
15. FDA (1998) Guidance for industry general considerations for pediatric pharmacokientics studies for drugs and biological products. US Department of Health and Human Services; Food and Drug Adminstration; Centre for Drug Evaluation and Research & Centre for Biologics Evaluation and Research, Rockville (Accessed 10 July, 2010)
16. Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, Wei R, Curtin LR, Roche AF, Johnson CL (2002) 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11:1-190
17. Anderson BJ, Allegaert K, Holford NH (2006) Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr 165:819-829 (Pubitemid 44627767)
18. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE (2003) Developmental pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med 349:1157-1167 (Pubitemid 37122329)
19. Anderson BJ, Allegaert K, Holford NH (2006) Population clinical pharmacology of children: general principles. Eur J Pediatr 165:741-746 (Pubitemid 44440510)
20. Siegel JH, Cerra FB, Coleman B, Giovannini I, Shetye M, Border JR, McMenamy RH (1979) Physiological and metabolic correlations in human sepsis. Invited commentary. Surgery 86:163-193
21. De Paepe P, Belpaire FM, Buylaert WA (2002) Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet 41:1135-1151 (Pubitemid 35398690)
22. Duffull S, Denman NG, Eccleston J, Kimko HC. WinPOPT. School of Pharmacy, University of Otago, Dunedin, New Zealand; Available from: http://www.winpopt. com/
23. Kimko HC, Duffull SB (2003) Simulation for designing clinical trials: a pharmacokinetic-pharmacodynamic modeling perspective. Marcel Dekker, New York
24. Waterhouse TH, Redmann S, Duffull SB, Eccleston JA (2005) Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients. J Pharmacokinet Pharmacodyn 32:521-545 (Pubitemid 41738439)
25. Duffull S, Waterhouse T, Eccleston J (2005) Some considerations on the design of population pharmacokinetic studies. J Pharmacokinet Pharmacodyn 32:441-457 (Pubitemid 41738435)
26. Bazzoli C, Retout S, Mentre F (2009) Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0. Comput Methods Programs Biomed 98:55-65
27. Gobburu J (2010) How to double success rate of pediatric trials? Conference proceedings of ASCPT, Atlanta, GA